

Appl. Serial No. 10/646,256
Amendment dated August 19, 2004
Reply to Office Action mailed July 29, 2004


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-5 (canceled)

6. (original) A compound of the formula:



wherein

R1 is a halogenated phenyl;

R2 is bicyclo[2.2.1]heptane, cyclopropane or cyclohexane; and,

R3 is NH₂, OH or 2-amino-3-phenylpropanamide.

7. (original) The compound of Claim 6, wherein R1 is 3,4-dichlorophenyl.

8. (original) The compound of Claim 6, wherein R1 is 3-chlorophenyl.

9. (original) The compound of Claim 6, wherein R3 is OH.


10. (original) The compound of Claim 6, wherein R3 is 2-amino-3-phenylpropanamide.

Appl. Serial No. 10/646,256
Amendment dated August 19, 2004
Reply to Office Action mailed July 29, 2004

11. (original) A pharmaceutical composition comprising a compound of Claim 6 or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

12-31 (cancelled)

32. (currently amended): A method of treating colon cancer for inhibiting protein prenylation comprising administering to a mammal in need of such treatment a therapeutically effective amount of contacting an isoprenoid transferase with a compound of the formula:



or a pharmaceutically-acceptable salt thereof, wherein

R1 is a halogenated phenyl;

R2 is bicyclo[2.2.1]heptane, cyclopropane or cyclohexane; and,

R3 is NH₂, OH or 2-amino-3-phenylpropanamide.

33. (original) The method of Claim 32, wherein R1 is 3,4-dichlorophenyl.

34. (original) The method of Claim 32, wherein R1 is 3-chlorophenyl.

35. (original) The method of Claim 32, wherein R3 is OH.

36. (original) The method of Claim 32, wherein R3 is 2-amino-3-phenylpropanamide.

37. (cancelled)

Appl. Serial No. 10/646,256
Amendment dated August 19, 2004
Reply to Office Action mailed July 29, 2004

38. (cancelled)

39. (original) The method of Claim 32, wherein said compound inhibits farnesyl-protein transferase.

40. (original) The method of Claim 32, wherein said compound modulates geranylgeranyl-protein transferase Type I.

41. (original) The method of Claim 40, wherein said compound has an IC50 value of about 60nM or less.

42. (original) The method of Claim 32, wherein said compound modulates geranylgeranyl-protein transferase Type II.

43-62 (cancelled)